Last reviewed · How we verify
Chlamydia mRNA Vaccine
At a glance
| Generic name | Chlamydia mRNA Vaccine |
|---|---|
| Sponsor | Sanofi |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chlamydia mRNA Vaccine CI brief — competitive landscape report
- Chlamydia mRNA Vaccine updates RSS · CI watch RSS
- Sanofi portfolio CI